Email updates

Keep up to date with the latest news and content from Arthritis Research & Therapy and BioMed Central.

Open Access Highly Accessed Research article

Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey

Michel De Bandt1*, Jean Sibilia2, Xavier Le Loët3, Sebastian Prouzeau4, Bruno Fautrel5, Christian Marcelli6, Eric Boucquillard7, Jean Louis Siame8, Xavier Mariette9 and the Club Rhumatismes et Inflammation

Author affiliations

1 Rheumatology Department, Hôpital Robert Ballanger, Aulnay sous Bois, France

2 CHU Hautepierre, Strasbourg, France

3 Hôpital Bois-Guillaume, Rouen, France

4 Hôpital de Saint Lo, Saint Lo, France

5 Hôpital Pitié Salpétrière, Assistance Publique-Hôpitaux de Paris, Paris, France

6 CHU côte de Nacre, Caen, France

7 Hôpital de Saint Pierre de la Réunion, St Pierre France

8 Polyclinique de Riaumont, Liévin, France

9 Hôpital de Bicêtre, Assistance Publique-Hôpitaux de Paris, Le Kremlin Bicêtre, France

For all author emails, please log on.

Citation and License

Arthritis Research & Therapy 2005, 7:R545-R551  doi:10.1186/ar1715

Published: 1 March 2005

Abstract

The development of drug-induced lupus remains a matter of concern in patients treated with anti-tumour necrosis factor (TNF) alpha. The incidence of such adverse effects is unknown. We undertook a retrospective national study to analyse such patients.

Between June and October 2003, 866 rheumatology and internal medicine practitioners from all French hospital centres prescribing anti-TNF in rheumatic diseases registered on the website of the 'Club Rhumatismes et Inflammation' were contacted by email to obtain the files of patients with TNF-induced systemic lupus erythematosus. Twenty-two cases were collected, revealing two aspects of these manifestations. Ten patients (six patients receiving infliximab, four patients receiving etanercept) only had anti-DNA antibodies and skin manifestations one could classify as 'limited skin lupus' or 'toxidermia' in a context of autoimmunity, whereas 12 patients (nine patients receiving infliximab, three patients receiving etanercept) had more complete drug-induced lupus with systemic manifestations and at least four American Congress of Rheumatology criteria. One patient had central nervous system manifestations. No patients had lupus nephritis. The signs of lupus occurred within a mean of 9 months (range 3–16 months) in patients treated with infliximab and within a mean of 4 months (range 2–5 months) in patients treated with etanercept. In all cases after diagnosis was determined, anti-TNF was stopped and specific treatment introduced in eight patients: two patients received intravenous methylprednisolone, four patients received oral steroids (15–35 mg/day), and two patients received topical steroids. Lupus manifestations abated within a few weeks (median 8 weeks, standard deviation 3–16) in all patients except one with longer-lasting evolution (6 months). At that time, cautious estimations (unpublished data from Schering Plough Inc. and Wyeth Inc.) indicated that about 7700 patients had been exposed to infliximab and 3000 to etanercept for inflammatory arthritides in France. It thus appears that no drug was more implicated than the other in lupus syndromes, whose incidence was 15/7700 = 0.19% with infliximab and 7/3800 = 0.18% with etanercept.

Clinicians should be aware that lupus syndromes with systemic manifestations may occur in patients under anti-TNF alpha treatment.